Bristol axes two early Celgene projects
Off-the-shelf Car-T from Caribou does enough at six months
Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.
Lung cancer switch does the job for Black Diamond
First data with the biotech’s new EGFR project prompts a 236% share price bump.
Nkarta plans its comeback
The company puts its faith in a new lymphodepletion regimen to overcome mediocre early results with its lead Car-NK therapy.
